Foghorn Therapeutics is developing a new class of medicines that target genetically determined dependencies within the chromatin regulatory system. Their proprietary Gene Traffic Control platform allows them to identify, validate, and potentially drug targets within the system. They are developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors. This new approach alters what our DNA has in store for us and rewrites destiny for millions of people living with disease.